Stroke was the fourth leading cause of death in the US last year, accounting for 162,600 deaths, according to preliminary data.

GLP-1 receptor agonists and SGLT2 inhibitors, two classes of medications most commonly prescribed to treat Type 2 diabetes or weight loss, may reduce the risk of heart attack, second strokes and death ...

In an analysis of more than 7,000 stroke survivors, those who were taking either a GLP1-receptor agonist or an SGLT2 inhibitor medication had a lower risk of a subsequent stroke, heart attack or death ...

In an analysis of more than 7,000 stroke survivors, those who were taking either a GLP1-receptor agonist or an SGLT2 ...

SGLT2 diabetes meds like Jardiance or Farxiga do the same, and also decrease risk of a follow-up stroke MONDAY, Nov. 11, 2024 ...

On the question of whether the benefits of sotagliflozin, an oral dual sodium-glucose co-transporter types 1 and 2 (SGLT1/SGLT2) inhibitor, outweigh the risks in this patient population, the committee ...

Empagliflozin, or Empa, is a medication often used to help people with type 2 diabetes manage their blood sugar. Now, ...

Health news and commentary gathered by MedPage Today staff ...

The Prescription Drug User Fee Act date refers to the deadline set by the FDA for reviewing a NDA or Biologics License Application.

The use of SGLT2 inhibitors vs sulfonylurea was associated with a reduced risk for incident gout and MACE among patients with type 2 diabetes with/at risk for gout.

Lexicon (LXRX) announced the peer-reviewed Journal of American Society of Nephrology, or JASN, has published a research paper analyzing the ...